Wedbush Has Negative Outlook for Ardelyx FY2026 Earnings

Ardelyx, Inc. (NASDAQ:ARDX - Free Report) - Wedbush decreased their FY2026 EPS estimates for shares of Ardelyx in a research note issued to investors on Friday, November 1st. Wedbush analyst L. Chico now expects that the biopharmaceutical company will post earnings per share of $0.06 for the year, down from their previous estimate of $0.08. Wedbush currently has a "Outperform" rating and a $11.00 price target on the stock. The consensus estimate for Ardelyx's current full-year earnings is ($0.25) per share. Wedbush also issued estimates for Ardelyx's FY2027 earnings at $0.38 EPS and FY2028 earnings at $0.66 EPS.

Ardelyx (NASDAQ:ARDX - Get Free Report) last posted its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.07) EPS for the quarter, topping analysts' consensus estimates of ($0.11) by $0.04. The company had revenue of $73.20 million during the quarter, compared to analysts' expectations of $55.03 million. Ardelyx had a negative return on equity of 46.86% and a negative net margin of 28.82%. Ardelyx's revenue was up 228.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.08) EPS.

Several other brokerages have also issued reports on ARDX. StockNews.com raised shares of Ardelyx from a "sell" rating to a "hold" rating in a report on Wednesday, July 31st. HC Wainwright reiterated a "buy" rating and set a $11.00 target price on shares of Ardelyx in a research report on Friday. Finally, Citigroup decreased their price target on shares of Ardelyx from $12.00 to $10.00 and set a "buy" rating for the company in a research report on Monday. Two research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $11.33.

Ardelyx Price Performance

Ardelyx stock traded down $0.20 during midday trading on Monday, reaching $5.89. The company's stock had a trading volume of 4,697,930 shares, compared to its average volume of 4,858,963. The company has a current ratio of 4.21, a quick ratio of 3.99 and a debt-to-equity ratio of 0.68. The stock has a market cap of $1.39 billion, a PE ratio of -19.63 and a beta of 0.92. Ardelyx has a 52 week low of $3.43 and a 52 week high of $10.13. The business has a 50-day moving average price of $6.06 and a 200-day moving average price of $6.32.

Insider Activity

In related news, insider David P. Rosenbaum sold 49,564 shares of Ardelyx stock in a transaction on Friday, September 27th. The shares were sold at an average price of $6.92, for a total transaction of $342,982.88. Following the completion of the transaction, the insider now owns 301,946 shares of the company's stock, valued at $2,089,466.32. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other Ardelyx news, CEO Michael Raab sold 25,000 shares of Ardelyx stock in a transaction that occurred on Monday, October 28th. The stock was sold at an average price of $5.91, for a total value of $147,750.00. Following the completion of the sale, the chief executive officer now directly owns 1,210,108 shares in the company, valued at approximately $7,151,738.28. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider David P. Rosenbaum sold 49,564 shares of the business's stock in a transaction that occurred on Friday, September 27th. The shares were sold at an average price of $6.92, for a total value of $342,982.88. Following the completion of the transaction, the insider now directly owns 301,946 shares in the company, valued at approximately $2,089,466.32. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 212,126 shares of company stock valued at $1,298,963. 5.90% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. Los Angeles Capital Management LLC raised its holdings in shares of Ardelyx by 51.8% during the third quarter. Los Angeles Capital Management LLC now owns 170,544 shares of the biopharmaceutical company's stock valued at $1,175,000 after purchasing an additional 58,219 shares during the period. Tyler Stone Wealth Management grew its stake in Ardelyx by 87.0% in the third quarter. Tyler Stone Wealth Management now owns 96,850 shares of the biopharmaceutical company's stock valued at $667,000 after acquiring an additional 45,055 shares during the period. China Universal Asset Management Co. Ltd. increased its holdings in shares of Ardelyx by 64.7% during the third quarter. China Universal Asset Management Co. Ltd. now owns 45,280 shares of the biopharmaceutical company's stock valued at $312,000 after acquiring an additional 17,792 shares in the last quarter. Wealth Enhancement Advisory Services LLC raised its position in shares of Ardelyx by 34.3% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 28,365 shares of the biopharmaceutical company's stock worth $195,000 after purchasing an additional 7,245 shares during the period. Finally, Values First Advisors Inc. lifted its holdings in shares of Ardelyx by 14.6% in the 3rd quarter. Values First Advisors Inc. now owns 46,282 shares of the biopharmaceutical company's stock worth $319,000 after purchasing an additional 5,890 shares in the last quarter. Institutional investors and hedge funds own 58.92% of the company's stock.

Ardelyx Company Profile

Ardelyx, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation.